
SMTI Stock Forecast & Price Target
SMTI Analyst Ratings
Bulls say
Sanara MedTech Inc. demonstrated robust growth in its surgical soft tissue repair products, with a 24% year-over-year sales increase to $23.4 million, attributed to heightened demand for its key offerings. Additionally, the company reported continued revenue growth with an anticipated increase of 13-17% for 2026, supported by a new contract with Vizient, enhancing market access and distribution efficiency. With a focus on operational improvements and the achievement of profitability in third-quarter 2025, Sanara MedTech's strategic initiatives position it favorably for future financial performance.
Bears say
Sanara MedTech Inc reported net revenue of $26.3 million, reflecting a year-over-year growth of 21.5% but falling short of projections, highlighting concerns about sustained revenue growth potential. The company faces substantial risks, including the possibility of lower-than-expected revenue growth, challenges in acquiring new customers, and difficulties in launching new products, which could further affect its financial performance. Additionally, the reduction of the EV/Revenue multiple from 4.3x to 3.0x indicates negative adjustments in market expectations due to the exclusion of telehealth from its business model.
This aggregate rating is based on analysts' research of Sanara MedTech Inc. and is not a guaranteed prediction by Public.com or investment advice.
SMTI Analyst Forecast & Price Prediction
Start investing in SMTI
Order type
Buy in
Order amount
Est. shares
0 shares